Stand alone validation of PRO's for myelofibrosis
Research type
Research Study
Full title
Standalone validation of PROs for myelofibrosis
IRAS ID
314132
Contact name
Helen Doll
Contact email
Sponsor organisation
AbbVie
Duration of Study in the UK
0 years, 3 months, 2 days
Research summary
This is an non-interventional, qualitative observational study, to confirm that two patient-reported measures that are used in clinical trials for patients with myelofibrosis are understandable to patients diagnosed with myelofibrosis and can accurately measure the symptoms and impacts of myelofibrosis. The goal is for these measures to best capture the experiences of living with myelofibrosis including what symptoms are most important and how these symptoms may impact the day-to-day lives of those living with myelofibrosis. In this study, for participants in the UK, we will collect feedback in the form of a two-part online survey.
N=150 survey participants from US, Canada and UK.
No interviews will be conducted with participants from the UK or Canada
REC name
Wales REC 3
REC reference
22/WA/0126
Date of REC Opinion
3 May 2022
REC opinion
Further Information Favourable Opinion